Decoding Annie Parker (2013)

The film runs two strands. One follows Annie Parker, whose life it is based on. The other follows the geneticist Mary-Claire King.

In the film's account, Annie is a child when her mother collapses and dies. Her older sister Joan later gets the same cancer and dies within months. Annie is then diagnosed with breast cancer herself. Surgery and chemotherapy follow, and her marriage to Paul falls apart. All the way through, she keeps telling doubtful doctors that this disease runs in her family, and that the pattern must mean something.

The other strand is set in a laboratory. King spends the 1980s at Berkeley looking for an inherited cause of breast cancer. Almost nobody thinks there is one. She gathers families with unusually high rates of the disease and uses linkage analysis. That method tracks how a trait travels through a family, in order to work out where the gene sits. In 1990 her team reports that BRCA1 is on chromosome 17.

Annie is diagnosed a second time. She remarries. Some years later a third cancer arrives. She survives each one. The film ends with King's finding known worldwide, and Annie holding the explanation she had argued for all along.

It premiered in April 2013 and reached American cinemas in May 2014.

The ending is discussed below.

The emotional core is true to the history, and that is the film's real achievement.

Before King's work, several breast cancers in one family were usually put down to chance. Cancer was seen as something that happened to individuals. A woman who said otherwise was not being brushed off out of malice. She was arguing against the settled view.

The film is good on how lonely that is. It is also good on a specific frustration: being told, kindly, that you are frightened rather than right.

It is good, too, on how an inherited cancer sits inside a family rather than in one body. It follows siblings, a mother and a daughter across decades. That is the right unit to look at for this kind of disease.

And it resists the tidy arc. Annie is diagnosed again and again over many years. Samantha Morton plays her as difficult, funny, angry and sexual rather than saintly. The science strand shows discovery as it really is. You recruit families. You wait years for data. You defend an unpopular idea while being patronised.

King's team at Berkeley reported where BRCA1 sits in 1990. She presented the result at a human genetics conference and published it in the journal Science.

Finding where a gene lives is not the same as having the gene. The sequence itself was cloned four years later, in 1994. That was done by scientists at the University of Utah, at the National Institute of Environmental Health Sciences, and at Myriad Genetics. An international race had run in between to pin down the exact spot.

That four-year gap is the part the film flattens. It offers a cleaner, more singular triumph than the record supports, and the people who finished the job largely vanish.

Annie's treatments are heavily compressed. Between cancers she looks tired in a photogenic way rather than truly ill. The years of checks between diagnoses are not there at all.

The ending also implies a straight line from discovery to answers. What actually followed was messier. There were counselling requirements. There were years of court cases over who owned the gene. And there was long uncertainty about what one particular gene change means for one particular family.

That last problem has not gone away. Some test results still come back as a variant of uncertain significance. It is neither reassurance nor a plan, and it is worth knowing that such a result exists before you agree to a test.

For most women, the practical question this film raises is the ordinary one.

The US Preventive Services Task Force recommends a screening mammogram every two years for women aged 40 to 74. That is a grade B recommendation, published in 2024.

Between appointments, report a new lump or thickening in the breast or underarm. Also report a change in the size or shape of a breast, dimpling or puckering of the skin, a nipple turning inward, discharge including blood, red or flaky skin, and pain that will not settle.

There is no population screening for BRCA1 or BRCA2. Nobody is offered a gene test as a matter of routine.

What the Task Force recommends, at grade B, is a two-step process. Step one applies to women whose own history, family history or ancestry is linked to harmful BRCA1 or BRCA2 changes. They should be assessed with a brief familial risk tool. That is a short set of questions, not a blood test. Step two follows only if the answers come back positive: genetic counselling, and then testing if counselling supports it.

For women without such a history, the Task Force recommends against routine assessment or testing. That is a grade D. Testing people at ordinary risk produces more confusion than benefit.

Some patterns should prompt the conversation. Breast cancer at a young age. Several affected relatives. Cancer in both breasts. Ovarian cancer in the family. Breast cancer in a male relative.

If a harmful change is found, the plan changes. Checks usually start earlier, and MRI is added alongside mammography. Ways of reducing risk are discussed too.

The science strand covers breast and ovarian cancer risk together. The two are not in the same position.

The Task Force recommends against screening for ovarian cancer in women who have no symptoms. That is a grade D, and it applies to women not known to carry a high-risk inherited syndrome. Women who do carry one are managed separately.

So a woman who learns she has a BRCA change gains an early-detection plan for her breast risk. She does not gain an equal one for her ovarian risk. The film does not make that clear, and it is one of the hardest parts of the conversation in a genetics clinic.

Cancer Explained is free and ad-free. Nothing is sold on this page. No sponsor sits behind it.

Did this page help you understand something about Decoding Annie Parker, or nudge you toward a question you had been avoiding? Reader support is what keeps this page on Decoding Annie Parker free, along with every other page here. Support our work.

Decoding Annie Parker is an uneven film built on one important idea. A patient's account of her own family was data, and medicine took a decade to treat it that way.

The version you can act on is smaller and still useful. Family history is a clinical fact. It belongs in your record. It should be updated when something changes. And it is what decides whether anyone offers you a risk assessment at all.

If several close relatives have had breast or ovarian cancer, raise it directly rather than waiting to be asked. Decoding Annie Parker cannot tell you what to watch for, but screening and possible warning signs can.

This page discusses Decoding Annie Parker for education. It is not medical advice, and nothing here is a judgement of anyone's real medical care. Spotted an error? Please email corrections@cancerexplained.org.